Karyopharm Therapeutics (NASDAQ:KPTI) Issues Earnings Results

Karyopharm Therapeutics (NASDAQ:KPTI) announced its quarterly earnings results on Wednesday. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.02, Zacks reports. The company had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million. Karyopharm Therapeutics updated its FY 2025 guidance to EPS.

Karyopharm Therapeutics Stock Down 4.8 %

Shares of KPTI opened at $0.60 on Thursday. The stock’s 50-day moving average price is $0.67 and its 200 day moving average price is $0.76. The firm has a market capitalization of $75.71 million, a price-to-earnings ratio of -0.53 and a beta of 0.06. Karyopharm Therapeutics has a 12-month low of $0.53 and a 12-month high of $1.70.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Karyopharm Therapeutics in a report on Thursday. StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Piper Sandler increased their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Monday, February 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).